ClinicalTrials.gg
TerminatedNCT02348359Updated Feb 11, 2022Results posted

X-82 to Treat Age-related Macular Degeneration

A Phase 2 interventional study of X-82 and Anti-VEGF in Age-Related Macular Degeneration (AMD), Macular Degeneration and Exudative Age-related Macular Degeneration, sponsored by Tyrogenex. Terminated at 35 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2022-02-11.

Sponsored by Tyrogenex · Phase 2, Interventional, and Treatment

Why this study was terminated
Interim analysis found study had achieved primary objective

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
157
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Enrollment
132nd of 491
157 · median 55
Started
2015
with 31 others
Phase 2
138 of 645
14 open now
Registered
304th of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 132nd largest by enrollment of the 491 interventional ones that give a count, is one of 32 that started in 2015, is one of 138 in phase 2, and was the 304th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of X-82 in the treatment of vision loss due to wet AMD.

Read the detailed description

Subjects will be randomized in a 1:1:1:1 ratio to the following dose groups:

  • X-82 50 mg plus ivt anti-VEGF prn
  • X-82 100 mg plus ivt anti-VEGF prn
  • X-82 200 mg plus ivt anti-VEGF prn
  • Placebo plus ivt anti-VEGF prn

Subjects will be treated for a total of 52 weeks with one of three doses of X-82 or placebo.

Primary Efficacy Outcome:

The primary efficacy outcome is the change in visual acuity score from Day -1 to 52 Weeks after randomization.

Safety Outcomes:

Systemic and ocular safety will be evaluate by assessing ECG, laboratory analyses, adverse events and serious adverse events.

Approximately 132 subjects will be randomized into one of the four arms (33 subjects per dose group).

03

Conditions studied

  • Age-Related Macular Degeneration (AMD)
  • Macular Degeneration
  • Exudative Age-related Macular Degeneration
  • AMD
  • Macular Degeneration, Age-related, 10
  • Eye Diseases
  • Retinal Degeneration
  • Retinal Diseases

Keywords

  • Vascular Endothelial Growth Factor (VEGF)
  • Platelet Derived Growth Factor (PDGF)
  • AMD
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants mush have wet AMD which has been diagnosed and treated with anti-VEGF in one or both eyes for at least 6 months prior to joining the study and has required at least two prior injections of intravitreal (ivt) anti-VEGF at intervals of not greater than 6 weeks for the past two injections in the eye that is selected to be the study eye.
  • Must have demonstrated a reduction in macular fluid or macular thickness in the study eye 14 days following an anti-VEGF injection at Screening Visit 1
  • Early Treatment Diabetic Retinopathy (ETDRS) Best Corrected Visual Acuity (BCVA) of 25 letters (20/320) or better in both eyes

Exclusion criteria

Exclusion Criteria:

  • Previous vitrectomy to the study eye within 30 days of Screening Visit 1
  • Choroidal neovascularization (CNV) due to causes other than AMD
  • Proliferative diabetic retinopathy in either eye
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
157 participants (actual)

Study arms

  • Experimental
    50 mg of X-82 plus ivt anti-VEGF prn

    Subject will administer one 50 mg tablet of X-82 and one placebo tablet once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.

    Drug: X-82 · Drug: Anti-VEGF

  • Experimental
    100 mg of X-82 plus ivt anti-VEGF prn

    Subject will administer two 50 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.

    Drug: X-82 · Drug: Anti-VEGF

  • Experimental
    200 mg of X-82 plus ivt anti-VEGF prn

    Subject will administer two 100 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.

    Drug: X-82 · Drug: Anti-VEGF

  • Placebo comparator
    Placebo plus ivt anti-VEGF prn

    Subject will administer two placebo tablets once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.

    Drug: Anti-VEGF · Drug: Placebo

Interventions

  • DrugX-82

    Also known as: X-82 tablets

  • Also known as: Aflibercept (Eylea), Ranibizumab (Lucentis), Bevacizumab (Avastin)

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Mean Change in Visual Acuity Score From Day -1 to Week52

    The primary outcome is the change in the visual acuity score from Day -1 to 52 weeks after randomization.

    Time frame: Week 52

07

Results

Posted Jun 27, 2018

Participant flow

This study was conducted at 39 sites in the United States. There were 36 sites that screened subjects and 3 sites that did not screen any subjects. A total of 157 subjects were randomly assigned and treated in the study.

Participant flow — Overall Study
Milestone50 mg of X-82 Plus Ivt Anti-VEGF Prn100 mg of X-82 Plus Ivt Anti-VEGF Prn200 mg of X-82 Plus Ivt Anti-VEGF PrnPlacebo Plus Ivt Anti-VEGF Prn
Started40393939
Completed29222527
Not completed11171412

Outcome measures

PrimaryMean Change in Visual Acuity Score From Day -1 to Week52

The primary outcome is the change in the visual acuity score from Day -1 to 52 weeks after randomization.

Time frame:
Week 52
Reported as:
Mean · number of letters
Mean Change in Visual Acuity Score From Day -1 to Week52
number of letters50 mg of X-82 Plus Ivt Anti-VEGF Prn100 mg of X-82 Plus Ivt Anti-VEGF Prn200 mg of X-82 Plus Ivt Anti-VEGF PrnPlacebo Plus Ivt Anti-VEGF Prn
Mean Change in Visual Acuity Score From Day -1 to Week520.2 ± 4.14-0.9 ± 6.571.7 ± 5.58-0.3 ± 10.63

Adverse events

Collected over All adverse events were collected and reported from time of participant study entry until discharge of last participant from the study. Individual subject participation in the study ranged from 0-14 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
50 mg of X-82 Plus Ivt Anti-VEGF Prn0/40 (0%)6/40 (15%)39/40 (97.5%)
100 mg of X-82 Plus Ivt Anti-VEGF Prn1/39 (2.6%)7/39 (17.9%)38/39 (97.4%)
200 mg of X-82 Plus Ivt Anti-VEGF Prn0/39 (0%)3/39 (7.7%)37/39 (94.9%)
Placebo Plus Ivt Anti-VEGF Prn0/39 (0%)2/39 (5.1%)34/39 (87.2%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
Event50 mg of X-82 Plus Ivt Anti-VEGF Prn100 mg of X-82 Plus Ivt Anti-VEGF Prn200 mg of X-82 Plus Ivt Anti-VEGF PrnPlacebo Plus Ivt Anti-VEGF Prn
lower gastrointestinal hemorrhageGastrointestinal disorders0/400/391/390/39
Chest painGeneral disorders0/400/391/390/39
sudden cardiac deathCardiac disorders0/401/390/390/39
EndopthalmitisInfections and infestations0/401/390/390/39
InfluenzaInfections and infestations0/401/390/390/39
PneumoniaInfections and infestations0/400/390/391/39
DehydrationMetabolism and nutrition disorders0/401/390/390/39
HypokalemiaMetabolism and nutrition disorders0/401/390/390/39
Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/401/390/390/39
B cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/400/391/390/39
Most frequent other events
Showing 10 of 72
Most frequent other events
Event50 mg of X-82 Plus Ivt Anti-VEGF Prn100 mg of X-82 Plus Ivt Anti-VEGF Prn200 mg of X-82 Plus Ivt Anti-VEGF PrnPlacebo Plus Ivt Anti-VEGF Prn
Hair color changeSkin and subcutaneous tissue disorders2/4010/3913/390/39
Alanine aminotransferase increasedInvestigations8/4011/399/392/39
Aspartate aminotransferase increasedInvestigations6/4010/398/391/39
DysgeusiaNervous system disorders3/405/3910/390/39
DiarrhoeaGastrointestinal disorders1/404/399/392/39
NasopharyngitisInfections and infestations7/402/395/392/39
FatigueGeneral disorders2/404/396/390/39
AlopeciaSkin and subcutaneous tissue disorders1/402/396/390/39
nauseaGastrointestinal disorders6/402/391/391/39
Urinary tract infectionInfections and infestations2/405/391/392/39

Baseline characteristics

All randomized subjects

Age, Continuous
Age, Continuous(years)50 mg of X-82 Plus Ivt Anti-VEGF Prn100 mg of X-82 Plus Ivt Anti-VEGF Prn200 mg of X-82 Plus Ivt Anti-VEGF PrnPlacebo Plus Ivt Anti-VEGF PrnTotal
Mean75.7 ± 8.2373.5 ± 8.3375.0 ± 7.6375.9 ± 7.6575.0 ± 7.95
Sex: Female, Male
Sex: Female, Male(Participants)50 mg of X-82 Plus Ivt Anti-VEGF Prn100 mg of X-82 Plus Ivt Anti-VEGF Prn200 mg of X-82 Plus Ivt Anti-VEGF PrnPlacebo Plus Ivt Anti-VEGF PrnTotal
Female2216182379
Male1823211678
Race (NIH/OMB)
Race (NIH/OMB)(Participants)50 mg of X-82 Plus Ivt Anti-VEGF Prn100 mg of X-82 Plus Ivt Anti-VEGF Prn200 mg of X-82 Plus Ivt Anti-VEGF PrnPlacebo Plus Ivt Anti-VEGF PrnTotal
American Indian or Alaska Native00000
Asian00112
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White40383838154
More than one race01001
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)50 mg of X-82 Plus Ivt Anti-VEGF Prn100 mg of X-82 Plus Ivt Anti-VEGF Prn200 mg of X-82 Plus Ivt Anti-VEGF PrnPlacebo Plus Ivt Anti-VEGF PrnTotal
United States40393939157
Best corrected visual acuity
Best corrected visual acuity(Number of letters)50 mg of X-82 Plus Ivt Anti-VEGF Prn100 mg of X-82 Plus Ivt Anti-VEGF Prn200 mg of X-82 Plus Ivt Anti-VEGF PrnPlacebo Plus Ivt Anti-VEGF PrnTotal
Mean72.3 ± 9.4171.2 ± 12.1771.9 ± 13.1768.8 ± 12.4371.0 ± 11.83
08

Study locations

35 sites
  • Tucson, Arizona, United States
  • Beverly Hills, California, United States
  • Huntington Beach, California, United States
  • Redlands, California, United States
  • Sacramento, California, United States
  • Colorado Springs, Colorado, United States
  • Golden, Colorado, United States
  • New London, Connecticut, United States
  • Fort Myers, Florida, United States
  • Lakeland, Florida, United States
  • Melbourne, Florida, United States
  • Miami, Florida, United States
  • Palm Beach Gardens, Florida, United States
  • Augusta, Georgia, United States
  • Lemont, Illinois, United States
  • Oak Forest, Illinois, United States
  • Indianapolis, Indiana, United States
  • Baltimore, Maryland, United States
  • Glen Burnie, Maryland, United States
  • Boston, Massachusetts, United States
  • Springfield, Massachusetts, United States
  • Portsmouth, New Hampshire, United States
  • Bloomfield, New Jersey, United States
  • Albany, New York, United States
  • New York, New York, United States
  • Asheville, North Carolina, United States
  • Charlotte, North Carolina, United States
  • Cleveland, Ohio, United States
  • Youngstown, Ohio, United States
  • Nashville, Tennessee, United States
  • Abilene, Texas, United States
  • Austin, Texas, United States
  • Houston, Texas, United States
  • The Woodlands, Texas, United States
  • Richmond, Virginia, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2015 to primary completion in Dec 2017, 32 months.

Results were first posted in Jun 2018, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2015
First posted
Jan 28, 2015
StartActual
Mar 16, 2015
Primary completionActual
Dec 12, 2017
CompletionActual
Jan 12, 2018
Results first posted
Jun 27, 2018
Last update
Feb 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02348359
Lead sponsor
Tyrogenex
Collaborators
SynteractHCR, International Drug Development Institute
Responsible party
Sponsor
First posted
Jan 28, 2015
Start date
Mar 16, 2015
Primary completion
Dec 12, 2017
Completion
Jan 12, 2018
Results posted
Jun 27, 2018
Last update
Feb 11, 2022

Study contacts

Daniel E Salazar, PhD
principal investigator · Study PI

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorolanib

Start the discussion